absorb.md

Brittany Whitmore

Chronological feed of everything captured from Brittany Whitmore.

podcast_episode / 1d ago

The Snooze Button: Baby & Toddler Sleep, Simplified: Trust The Scoop: Formula Safety, Sanity, and Support with The Formula Mom, Mallory Whitmore

<p>Whether you're annoyed by judgey comments, disappointed your feeding journey looks different than you imagined, or just overwhelmed by all the options available, formula feeding comes with it's own sets of challenges. And in 2026, it comes with new concerns - safety, recalls, did someone say seed oils?!</p><p>Well great news, Mallory Whitmore of the popular IG account The Formula Mom, is here to put your mind at ease. Mallory, a veteran Mom, infant feeding tech, and advocate, is here to share her wisdom with you. We talk about everything from recalls and safety to common misconceptions and...

article / 1d ago

About iComply - Medium

Brittany Whitmore. 306 followers. Follow. PR Specialist for Disruptive Industries (Professional Noisemaker), Speaker, Emcee, Entrepreneur ...

article / 1d ago

STAT Brand Studio

Brittany Whitmore. Executive producer, STAT Brand Studio. Denise Thayer. VP, Advertising & Revenue Operations. Jesse McQuarters. Editor, STAT Brand Studio.

article / 1d ago

Brittany Whitmore - CDM Summit

Brittany Whitmore is the CEO of Exvera Communications, a PR firm specializing in communications for disruptive technology, ...

article / 1d ago

I Have a Dream - LinkedIn

Brittany Whitmore. PR Specialist for Disruptive Industries… Published ... Well put together Brittany, I had a good time reading your blog post!!

article / 1d ago

Britt Whitmore - STAT | LinkedIn

Spanish. Professional working proficiency. English. Native or bilingual proficiency. Websites. Company Website: https://www.statnews.com/staff/brittany-whitmore ...

paper / 1d ago

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

Summary Background Sodium-glucose co-transporter 2 inhibitors (SGLT2i) slow progression of chronic kidney disease (CKD) but there is no randomised evidence of their effects on health-related quality of life (QoL) and healthcare use. We explored the effects of empagliflozin on health-related QoL, healthcare use and UK healthcare costs in the EMPA-KIDNEY trial. Methods EMPA-KIDNEY, a randomised, double blind, placebo-controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included participants aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 20 to <45 mL/min/1.73 m2, or with an eGFR of 45 to <90 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio (uACR) of ≥200 mg/g at screening. They were randomly assigned (1:1) to receive empagliflozin 10 mg once daily or matching placebo. We estimated the effect of empagliflozin (UK£1.31/day) on exploratory outcomes (unless otherwise specified) of quality-adjusted life years (QALYs), UK costs (2023 UK£) of hospital admissions (a prespecified secondary outcome), concomitant medications and end-stage kidney disease (ESKD; a prespecified tertiary outcome) management over 2 years on study treatment (median active-trial follow-up) and on ESKD costs over 2 further years off study treatment (median post-trial follow-up) using shared parameter models analysing outcomes together with time to death or negative binomial models. The trial is registered with ClinicalTrials.gov, NCT03594110. Findings Between May 15, 2019 and April 16, 2021, 6609 participants were randomly assigned to empagliflozin (3304 participants) or matching placebo (3305 participants) in the active-trial which lasted for a median of 2.0 years. Among them, 4891 (74%) were enrolled in the post-trial follow-up. Per participant allocated to empagliflozin over 2 years, total empagliflozin cost was £826 (95% confidence interval: 818 to 835), QALYs were 0.012 higher (0.001 to 0.022), with less cost for hospital admission (−£239, −449 to −29), concomitant medications (−£130, −214 to −47), and management of ESKD (−£208, −414 to −2) compared to placebo. Over a further 2 years of post-trial follow-up off study treatment, there were additional per participant ESKD cost savings (−£842, −1441 to −242), resulting in net total healthcare cost of −£593 (−1384 to 198) over 4 years. The probability of 2 years of empagliflozin treatment being cost-effective at £20 K threshold in the UK was 43% over 2 years of follow-up and 91% over 4 years. The relative effects of empagliflozin on each cost component were similar across categories by baseline levels of eGFR, uACR and diabetes status, with larger reductions in healthcare costs estimated in categories at higher risk of CKD progression. Interpretation In EMPA-KIDNEY, 2 years treatment with empagliflozin improved QALYs, and reduced use and cost of other healthcare, resulting in high likelihood of cost-effectiveness across a broad range of patients with CKD. The study's key limitation is its relatively short active treatment period and follow-up duration, which may lead to underestimation of the cost-effectiveness of long-term SGLT2i treatment in CKD. Funding 10.13039/100008349Boehringer Ingelheim, Germany; 10.13039/100004312Eli Lilly, USA; 10.13039/501100000265Medical Research Council, UK; 10.13039/501100000274British Heart Foundation, UK; 10.13039/501100023699Health Data Research, UK; 10.13039/501100000272National Institute for Health and Care Research, UK.

paper / 1d ago

The PHANGS-MUSE/HST-Hα nebulae catalogue. Parsec-scale resolved structure, physical conditions, and stellar associations across nearby galaxies

We present the PHANGS-MUSE/HST-Hα nebulae catalogue, comprising spatially resolved nebulae across 19 nearby star-forming galaxies (D<20,Mpc), based on high-resolution Hα imaging from HST, homogenised to a fixed (10,pc) physical resolution and sensitivity. Combined with MUSE integral field spectroscopy, this enables robust classification of H ii regions and the separation of planetary nebulae and supernova remnants. We derive electron densities for H ii regions using S ii diagnostics and adopt direct or representative electron temperatures for consistent physical characterisation. Nebular sizes are measured using circularised radii and intensity-weighted second moments, yielding a median radius of approximately 20,pc and extending down to (sub-)parsec (deconvolved) radii. A structural complexity score is introduced via hierarchical segmentation to trace substructure, highlighting that around a third of the regions are complexes containing several individual clusters and bubbles, with an increased fraction of these regions in galactic centres. A luminosity–size relation, calibrated using the resolved HST sample, is applied to MUSE nebulae, allowing the recovery of nebular sizes down to ∼1,pc and providing statistical completeness beyond the HST detection limit. Comparisons with classical Strömgren radii indicate that observed sizes are systematically larger, corresponding to typical volume filling factors with a fontcolor median of ε ∼ 0.22 (10th–90th percentile 0.06–0.78), with larger regions exhibiting progressively lower values. We associate H ii regions with stellar populations from the PHANGS-HST association catalogue, finding median ages of ∼3,Myr and typical stellar masses of around $10^4–10^5$,M_⊙, supporting the link between ionised nebular and young stellar populations. We also assess the impact of diffuse ionised gas on emission-line diagnostics and after removing confirmed supernova remnants, find no strong variation in line ratios with nebular resolution, indicating minimal systematic bias in the MUSE catalogue. This dataset establishes a detailed, spatially resolved connection between nebular structure and ionising sources, and provides a benchmark for future studies of feedback, DIG contributions, and star formation regulation in the ISM, especially in combination with matched high-resolution observations. fontcolor The full catalogue is made publicly available in machine-readable format.